GlassScriptPhysician profile
Glenn Arthur Lorentz
NPI 1295301927
$1,496.31
in general payments reported to CMS, 2019-2025
16 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.83 · 2024: $362 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.38 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $275.12 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $161.20 | 2024-2025 | |
| Glaxosmithkline, LLC. | $109.65 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $103.46 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $79.59 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $74.34 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $72.33 | 2025 | |
| Seqirus USA INC | $71.93 | 2024-2025 | Flucelvax, Fluad |
| Paratek Pharmaceuticals, INC. | $66.25 | 2024-2025 | Nuzyra, Xhance |
| Madrigal Pharmaceuticals | $56.82 | 2025 | Rezdiffra |
| Corcept Therapeutics | $32.46 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $25.88 | 2025 | Eliquis |
| Ardelyx, INC. | $24.57 | 2024 | Ibsrela |
| Axsome Therapeutics, INC. | $24.53 | 2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.80 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Lorentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.